Latest News

Q1 2022 assessment of HCV treatment access in ADAPs and Medicaid with DAA coverage and harm reduction data.

Q4 2021 Watch covering HCV drug formulary updates, ADAP and Medicaid changes, and pandemic impact on care.

Q3 2021 quarterly review of HCV drug access across ADAPs and Medicaid with harm reduction program updates.

Study of 109,283 patients links HIV status and viral hepatitis coinfection to significantly increased liver cancer rates.

UNAIDS report highlights HIV-HCV coinfection rates among people who inject drugs globally and in the US.

Quarterly update on HCV treatment coverage across ADAPs, Medicaid, Veterans programs, and patient assistance options.

Quarterly Watch covering HCV treatment access across ADAPs and Medicaid, harm reduction programs, and COVID-19 impact on care.

CANN outlines advocacy priorities for the Biden era, from 340B reform and drug pricing to HIV criminalization and health equity.